Xu L, Shen T, Li Y, Wu X
Clin Rev Allergy Immunol. 2025; 68(1):29.
PMID: 40085180
DOI: 10.1007/s12016-025-09041-6.
Wang H, Xu P, Yin K, Wang S
Front Immunol. 2025; 16:1521196.
PMID: 40066451
PMC: 11891544.
DOI: 10.3389/fimmu.2025.1521196.
Zhong Y, Zhang R, Lu L, Tan H, You Y, Mao Y
Cell Commun Signal. 2025; 23(1):126.
PMID: 40057764
PMC: 11889898.
DOI: 10.1186/s12964-025-02130-1.
Cates K, Hung V, Barna M
Philos Trans R Soc Lond B Biol Sci. 2025; 380(1921):20230378.
PMID: 40045784
PMC: 11883435.
DOI: 10.1098/rstb.2023.0378.
Biayna J, Dumbovic G
Genome Biol. 2025; 26(1):45.
PMID: 40033325
PMC: 11874642.
DOI: 10.1186/s13059-025-03507-8.
Phenylpyrazoles as Inhibitors of the mA RNA-Binding Protein YTHDF2.
Qiu X, Kemker C, Goebel G, Lampe P, Wallis N, Schiller D
JACS Au. 2025; 5(2):618-630.
PMID: 40017738
PMC: 11862924.
DOI: 10.1021/jacsau.4c00754.
De novo basecalling of RNA modifications at single molecule and nucleotide resolution.
Cruciani S, Delgado-Tejedor A, Pryszcz L, Medina R, Llovera L, Novoa E
Genome Biol. 2025; 26(1):38.
PMID: 40001217
PMC: 11853310.
DOI: 10.1186/s13059-025-03498-6.
A novel mechanism of FTO modulating the progression of endometriosis through mediating the m6A methylation of GEF-H1 in a YTHDF1-dependent manner.
Ding X, Zhang H, Chen J, Yang M, Huang Z, Lei Y
Mol Med. 2025; 31(1):78.
PMID: 40000966
PMC: 11863856.
DOI: 10.1186/s10020-025-01130-8.
The YTHDC1 reader protein recognizes and regulates the lncRNA MEG3 following its METTL3-mediated mA methylation: a novel mechanism early during radiation-induced liver injury.
Song G, Yu Q, Xing X, Fan X, Xu S, Zhang W
Cell Death Dis. 2025; 16(1):127.
PMID: 39994235
PMC: 11850776.
DOI: 10.1038/s41419-025-07417-2.
The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.
Shi T, Zhang H, Chen Y
Cell Biosci. 2025; 15(1):27.
PMID: 39987091
PMC: 11846233.
DOI: 10.1186/s13578-025-01368-z.
Silencing YTHDF2 Induces Apoptosis of Neuroblastoma Cells In a Cell Line-Dependent Manner via Regulating the Expression of DLK1.
Hua Z, Gong B, Li Z
Mol Neurobiol. 2025; .
PMID: 39979690
DOI: 10.1007/s12035-025-04759-y.
Molecular mechanisms of m6A modifications regulating tumor radioresistance.
Shen R, Jiang Z, Wang H, Zheng Z, Jiang X
Mol Med. 2025; 31(1):64.
PMID: 39972266
PMC: 11837317.
DOI: 10.1186/s10020-025-01121-9.
Deciphering the interplay between SETD2 mediated H3K36me3 and RNA N6-methyladenosine in clear cell renal cell carcinoma (ccRCC).
Shaikh S, Zhao X, Wagner R, Pan X, Hlady R, Wang L
Epigenetics. 2025; 20(1):2456418.
PMID: 39874221
PMC: 11776469.
DOI: 10.1080/15592294.2025.2456418.
The role of N-methyladenosine (mA) mRNA modifications in herpesvirus infections.
Verhamme R, Favoreel H
J Virol. 2025; 99(2):e0172324.
PMID: 39868828
PMC: 11852997.
DOI: 10.1128/jvi.01723-24.
Single-base mA epitranscriptomics reveals novel HIV-1 host interaction targets in primary CD4 T cells.
Huang S, Zhao Y, Phillips S, Wilms B, He C, Wu L
bioRxiv. 2025; .
PMID: 39803509
PMC: 11722377.
DOI: 10.1101/2024.12.31.630958.
SARS-CoV-2 and HCoV-OC43 regulate host m6A modification via activation of the mTORC1 signalling pathway to facilitate viral replication.
Zhou S, Hui X, Wang W, Zhao C, Jin M, Qin Y
Emerg Microbes Infect. 2025; 14(1):2447620.
PMID: 39745173
PMC: 11852242.
DOI: 10.1080/22221751.2024.2447620.
Loss of YTHDC1 mA reading function promotes invasiveness in urothelial carcinoma of the bladder.
Xu J, Koch J, Schmidt C, Nientiedt M, Neuberger M, Erben P
Exp Mol Med. 2024; 57(1):118-130.
PMID: 39741187
PMC: 11799412.
DOI: 10.1038/s12276-024-01377-x.
Emerging role of small RNAs in inflammatory bowel disease and associated colorectal cancer (Review).
Qiu W, Akanyibah F, Xia Y, Ocansey D, Mao F, Liang Y
Int J Mol Med. 2024; 55(2).
PMID: 39704210
PMC: 11670865.
DOI: 10.3892/ijmm.2024.5474.
FTO Facilitates Cervical Cancer Malignancy Through Inducing m6A-Demethylation of PIK3R3 mRNA.
Chen B, Wang L, Li X, Ren C, Gao C, Ding W
Cancer Med. 2024; 13(24):e70507.
PMID: 39692250
PMC: 11653219.
DOI: 10.1002/cam4.70507.
Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.
Yu A, Fu L, Jing L, Wang Y, Ma Z, Zhou X
Cell Death Differ. 2024; .
PMID: 39672819
DOI: 10.1038/s41418-024-01434-y.